Study Links GLP-1 Drugs to Higher Rates of Nail Detachment

Controlled Study Finds Increased Nail and Hair Disorders

Glucagon-like peptide-1 (GLP-1) receptor agonists are associated with higher rates of nail detachment, nail discoloration, and hair loss, according to research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026. Investigators evaluated 575 individuals taking GLP-1 medications and compared them with 1,329 control participants who had obesity or type 2 diabetes but had never used the drugs. The study recruited participants across France, the United States, Brazil, and Mexico.

Participants taking GLP-1 medications experienced nail detachment at more than four times the rate of nonusers. The condition, in which the nail separates from the skin underneath it, occurred in 39 percent of GLP-1 users compared with 9 percent of controls. Overall, 66 percent of GLP-1 users reported at least one nail disorder, compared with 53 percent of nonusers.

Weight Loss Does Not Fully Account for the Differences

Weight loss alone does not fully explain the higher frequency of nail issues seen among people taking GLP-1 medications. Rapid weight change can alter nutrition and physiology, which can affect nail and hair growth. When researchers restricted their evaluation to participants who had lost weight, GLP-1 users continued to report significantly more nail problems than nonusers who also lost weight.

Nail discoloration also appeared at higher frequencies in the treated group. The study recorded nail discoloration in 46 percent of GLP-1 users, compared with 17 percent of nonusers. A companion study examining the same cohort identified unusual hair loss in 50 percent of GLP-1 users, compared with 34 percent of controls.

Prior Conditions and Confounding Factors Narrow the Gap

The observational findings demonstrate a statistical association rather than direct causation. Approximately half of the participants using GLP-1 medications reported experiencing nail problems prior to starting treatment. Study author Dr. Charles Taïeb stated that while the findings show a clear link, events occurring during treatment are not necessarily caused by the medication itself.

Statistical adjustments for baseline skin conditions and nutritional deficiencies narrowed the gap between the two cohorts. Following those adjustments, reports of nail detachment and discoloration remained approximately two to three times more common among GLP-1 users. Further clinical research is required to identify the biological mechanisms involved.

Practical Context for People Managing Metabolic Health

Patients who notice nail separation, unusual color changes, or scalp irritation should discuss those symptoms with their prescribing clinician. Clinicians can examine the nail bed to rule out fungal infections, physical trauma, or nutritional shortages. Blood tests can also establish whether mineral or vitamin levels require attention.

Patients should avoid stopping prescribed metabolic therapies without guidance from their healthcare team. Abrupt cessation of GLP-1 therapies can lead to rapid increases in blood glucose levels and weight regain. A clinician or dermatologist can help manage skin and nail symptoms while keeping metabolic treatment goals intact.